The year ahead in pharma
Our CEO, Chris Molloy, was recently asked to share his thoughts on the challenges and opportunities facing pharma and healthcare in 2018.
Here are Chris’ thoughts on Brexit:
“Clearly the major impact of Brexit remains uncertain. We need to calmly look beyond; to the reality of a regional change within a global industry. As innovators we need to look for the opportunities change brings. The quality of the UK’s MHRA has traditionally had a strong influence on European Medicines Regulation and I do not see that stopping. While the UK will be outside the EU, the industry and the expert opinion remains in the UK, and biology knows no borders. I am confident that the transition will be managed and that both organisations will continue to collaborate closely in developing regional opinions and best practice. The post-Brexit world does give the UK the potential to carve a distinct role for itself in discovery and early clinical development.”